Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 02 2021
Historique:
received: 09 12 2020
accepted: 28 01 2021
entrez: 20 2 2021
pubmed: 21 2 2021
medline: 3 3 2021
Statut: epublish

Résumé

SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. This prompted investigation of whether or not asymptomatic disease results in measurable immune activation post-infection. Immune activation following asymptomatic SARS-CoV-2 infection was characterized through a comparative investigation of the immune cell transcriptomes from 43 asymptomatic seropositive and 52 highly exposed seronegative individuals from the same community 4-6 weeks following a superspreading event. Few of the 95 individuals had underlying health issues. One seropositive individual reported Cystic Fibrosis and one individual reported Incontinentia pigmenti. No evidence of immune activation was found in asymptomatic seropositive individuals with the exception of the Cystic Fibrosis patient. There were no statistically significant differences in immune transcriptomes between asymptomatic seropositive and highly exposed seronegative individuals. Four positive controls, mildly symptomatic seropositive individuals whose blood was examined 3 weeks following infection, showed immune activation. Negative controls were four seronegative individuals from neighboring communities without COVID-19. All individuals remained in their usual state of health through a five-month follow-up after sample collection. In summary, whole blood transcriptomes identified individual immune profiles within a community population and showed that asymptomatic infection within a super-spreading event was not associated with enduring immunological activation.

Identifiants

pubmed: 33608566
doi: 10.1038/s41598-021-83110-6
pii: 10.1038/s41598-021-83110-6
pmc: PMC7895922
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4243

Commentaires et corrections

Type : UpdateOf
Type : UpdateOf

Références

Genes Immun. 2020 Aug;21(4):260-262
pubmed: 32606316
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
Tuberculosis (Edinb). 2017 Dec;107:48-58
pubmed: 29050771
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
J Cyst Fibros. 2020 May;19(3):355-358
pubmed: 32376098
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Hormones (Athens). 2021 Mar;20(1):219-221
pubmed: 32676935
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
JAMA Intern Med. 2020 Nov 01;180(11):1447-1452
pubmed: 32780793
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Respir Med. 2020 Aug - Sep;170:106062
pubmed: 32843180
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
J Med Virol. 2021 Feb;93(2):820-830
pubmed: 32691881
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32501293
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748

Auteurs

Hye Kyung Lee (HK)

Laboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Ludwig Knabl (L)

Institute of Hygiene and Medical Microbiology & Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria. ludwig.knabl@tyrolpath.at.
Pathologie-Labor, 6020 Zams, Austria. ludwig.knabl@tyrolpath.at.

Lisa Pipperger (L)

Institute of Hygiene and Medical Microbiology & Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Andre Volland (A)

Institute of Hygiene and Medical Microbiology & Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Priscilla A Furth (PA)

Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.

Keunsoo Kang (K)

Laboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.
Department of Microbiology, Dankook University, Cheonan, 31116, South Korea.

Harold E Smith (HE)

Laboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD, 20892, USA.

Ludwig Knabl (L)

Krankenhaus St.Vinzenz Zams, 6511 Zams, Austria.

Romuald Bellmann (R)

Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University Innsbruck, 6020 Innsbruck, Austria.

Christina Bernhard (C)

Hospital Kufstein, 6330 Kufstein, Austria.

Norbert Kaiser (N)

Bezirkskrankenhaus St. Johann in Tirol, 6380 St. Johann in Tirol, Austria.

Hannes Gänzer (H)

Bezirkskrankenhaus Schwaz, 6130 Schwaz, Austria.

Mathias Ströhle (M)

Intensive Care, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Andreas Walser (A)

Ordination (Private Practice), 6561 Ischgl, Austria.

Dorothee von Laer (D)

Institute of Hygiene and Medical Microbiology & Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Lothar Hennighausen (L)

Laboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD, 20892, USA. lotharh@niddk.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH